Foghorn Therapeutics (NASDAQ:FHTX - Get Free Report) is expected to be releasing its earnings data before the market opens on Thursday, March 6th. Analysts expect Foghorn Therapeutics to post earnings of ($0.43) per share and revenue of $8.56 million for the quarter.
Foghorn Therapeutics Stock Up 4.8 %
Shares of Foghorn Therapeutics stock traded up $0.22 during mid-day trading on Friday, hitting $4.85. The stock had a trading volume of 102,315 shares, compared to its average volume of 149,493. The firm has a 50-day moving average of $4.76 and a two-hundred day moving average of $6.79. The firm has a market cap of $269.72 million, a P/E ratio of -2.53 and a beta of 3.18. Foghorn Therapeutics has a 12-month low of $3.86 and a 12-month high of $10.25.
Analyst Ratings Changes
FHTX has been the topic of a number of research analyst reports. B. Riley initiated coverage on shares of Foghorn Therapeutics in a research note on Thursday, January 30th. They issued a "buy" rating and a $10.00 price target on the stock. Jefferies Financial Group dropped their price target on Foghorn Therapeutics from $18.00 to $14.00 and set a "buy" rating on the stock in a research note on Monday, December 16th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $13.00 price target (down from $20.00) on shares of Foghorn Therapeutics in a report on Tuesday, December 17th. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $13.17.
Check Out Our Latest Research Report on Foghorn Therapeutics
About Foghorn Therapeutics
(
Get Free Report)
Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Featured Articles
Before you consider Foghorn Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Foghorn Therapeutics wasn't on the list.
While Foghorn Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
